Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by a twin strep tag.
The protein has a calculated MW of 30.1 kDa & 34.1 kDa. The protein migrates as 38-43 kDa and 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Cynomolgus IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag (Cat. No. ILG-C5284) is more than 90% and the molecular weight of this protein is around 90-120 kDa verified by SEC-MALS.
Immobilized Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) at 5 μg/mL (100 μL/well) can bind Cynomolgus IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag (Cat. No. ILG-C5284) with a linear range of 1-78 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bempegaldesleukin | BMS-986321; ONO-7911; NKTR-214 | Phase 3 Clinical | Nektar Therapeutics | Coronavirus Disease 2019 (COVID-19); Melanoma; Neoplasm Metastasis; Lymphoma; Glioma; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Solid tumours; Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia; Medulloblastoma; Rhabdomyosarcoma; Head and Neck Neoplasms; Ependymoma; Skin Melanoma | Details |
GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Vulvar Neoplasms; Sarcoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
Pegenzileukin | THOR-707; SAR-444245 | Phase 2 Clinical | Synthorx Inc | Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Esophageal adenocarcinoma; Oropharyngeal Neoplasms; Intestinal Neoplasms; Multiple Myeloma; Mesothelioma; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms | Details |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
LTC-004 | LTC004; LTC-004 | Phase 2 Clinical | Leto Laboratories Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Sarcoma; Colorectal Neoplasms | Details |
IAP-0971 | IAP-0971 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
TransCon IL-2 β/γ | Phase 2 Clinical | Ascendis Pharma A/S | Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Skin Neoplasms; Skin Melanoma; Carcinoma, Ovarian Epithelial; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Ovarian Neoplasms; Solid tumours | Details |
Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma | Details |
BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
STK-009 | STK-009 | Phase 1 Clinical | Synthekine Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
FB-102 | FB-102; FB102 | Phase 1 Clinical | Forte Biosciences Inc | Alopecia Areata; Graft vs Host Disease; Vitiligo; Malabsorption Syndromes | Details |
NL-201 (Neoleukin Therapeutics) | NL-201 | Phase 1 Clinical | Neoleukin Therapeutics Inc | Solid tumours | Details |
Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.